VJHemOnc Podcast
Medical
The Video Journal of Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjhemonc.com
Location:
United States
Description:
The Video Journal of Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjhemonc.com
Language:
English
Website:
https://www.vjhemonc.com
Episodes
Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome
4/26/2024
Graft-versus-host disease (GvHD) is a common complication following allogeneic stem cell transplantation (alloSCT), which is typically classified as acute or...
The post Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome appeared first on VJHemOnc.
Duration:00:22:51
The importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTs
4/11/2024
In recent years, there has been great emphasis placed on the importance of cardio-oncology, with both cardiologists and hematologists highlighting...
The post The importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTs appeared first on VJHemOnc.
Duration:00:43:52
Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification
4/4/2024
Smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) are two well-known precursor conditions to multiple myeloma, and the...
The post Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification appeared first on VJHemOnc.
Duration:00:22:22
CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors
3/28/2024
Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS) are considered precursor diseases to hematologic malignancies,...
The post CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors appeared first on VJHemOnc.
Duration:00:13:02
Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception
3/22/2024
Monoclonal B-cell lymphocytosis (MBL) is a condition characterized by the presence of an abnormal increase in B lymphocytes in the...
The post Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception appeared first on VJHemOnc.
Duration:00:09:40
The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT
3/15/2024
The introduction of CAR-T therapy has revolutionized the myeloma treatment landscape, offering a promising therapeutic approach for patients with relapsed/refractory...
The post The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT appeared first on VJHemOnc.
Duration:00:13:01
Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology
3/7/2024
While there have been advances in the treatment and management of amyloidosis in recent years, diagnosis remains a challenge due...
The post Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology appeared first on VJHemOnc.
Duration:00:33:31
Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy
2/29/2024
Although CAR-T cells have revolutionized the treatment of hematological malignancies, there are several important factors that must be addressed regarding...
The post Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy appeared first on VJHemOnc.
Duration:00:13:02
Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks
2/22/2024
The treatment landscape of acute lymphoblastic leukemia (ALL) has transformed with the introduction of novel immunotherapeutic agents, including CAR-T cells...
The post Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks appeared first on VJHemOnc.
Duration:00:12:59
Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents
2/16/2024
The treatment landscape of acute myeloid leukemia (AML) has transformed in recent years with the introduction of novel targeted agents,...
The post Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents appeared first on VJHemOnc.
Duration:00:12:10
Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023
2/8/2024
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms which can be categorized into lower- and higher-risk disease (LR-MDS;...
The post Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023 appeared first on VJHemOnc.
Duration:00:18:17
Key updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicine
1/31/2024
In the last decade, the treatment landscape of thalassemia has been transformed with the introduction of novel therapies. With several...
The post Key updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicine appeared first on VJHemOnc.
Duration:00:12:22
Updates, challenges and novel agents being explored in BPDCN
1/25/2024
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and rare hematological malignancy associated with poor prognosis. Several challenges remain...
The post Updates, challenges and novel agents being explored in BPDCN appeared first on VJHemOnc.
Duration:00:09:49
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets
1/18/2024
The treatment and management of patients with multiple myeloma is continually evolving, giving rise to novel prognostic tools and therapeutic...
The post Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets appeared first on VJHemOnc.
Duration:00:18:18
Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy
1/12/2024
In recent years, the treatment landscape of sickle cell disease (SCD) has been revolutionized with the introduction of novel agents,...
The post Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy appeared first on VJHemOnc.
Duration:00:11:05
ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis
1/5/2024
In recent years, the treatment and management of light chain (AL) amyloidosis has transformed with the introduction of novel agents....
The post ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis appeared first on VJHemOnc.
Duration:00:10:29
MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF
12/22/2023
The treatment of the BCR-ABL1-negative myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), has transformed...
The post MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF appeared first on VJHemOnc.
Duration:00:17:13
iwNHL 2023 Session V: Expanding the CAR platform in NHL
12/15/2023
The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as...
The post iwNHL 2023 Session V: Expanding the CAR platform in NHL appeared first on VJHemOnc.
Duration:00:10:59
iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials
12/7/2023
The biennial International Workshop on Chronic Lymphocytic LeukemiaTM (iwCLL 2023) was held recently in Boston, MA, and brought together experts who...
The post iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials appeared first on VJHemOnc.
Duration:00:20:50
iwNHL 2023 Session IV: Novel therapies in NHL: BTK inhibitors, BTK degraders, and bispecific antibodies
12/1/2023
The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as...
The post iwNHL 2023 Session IV: Novel therapies in NHL: BTK inhibitors, BTK degraders, and bispecific antibodies appeared first on VJHemOnc.
Duration:00:15:34